GLP-1 RAs have established their role in cardiovascular disease treatment beyond diabetes, with proven MACE reduction, HFpEF benefits, and emerging indications in CKD and peripheral artery disease.
CV standard of careGLP-1 drugs have evolved from diabetes medications to essential cardiovascular drugs — proven across heart attacks, heart failure, and kidney disease
What the researchers found
GLP-1 RAs: established cardiovascular role with proven MACE reduction, HFpEF benefits, kidney protection, and emerging PAD/AF benefits — cardiovascular standard of care beyond diabetes.
Why it matters
GLP-1 drugs are becoming as important for cardiology as statins. Understanding their full cardiovascular profile is essential.
How the study worked
Review of GLP-1 RA cardiovascular evidence and evolving clinical positioning.
What this study cannot tell us
Short review (840 chars abstract).
How to read the evidence
Review of landmark cardiovascular trial evidence.
When this study was published
Published in 2025.
The bigger picture
GLP-1 drugs are establishing themselves as the fourth pillar of cardiovascular prevention alongside statins, RAAS inhibitors, and SGLT2 inhibitors.
Questions still open
- Should all cardiovascular patients receive GLP-1 drugs?
- How should GLP-1 drugs be integrated with existing CV regimens?
- Will insurance cover GLP-1 drugs for CV prevention without diabetes?
Common questions
Are GLP-1 drugs heart medicines now?
Do I need diabetes to get GLP-1 drugs for my heart?
Read the original research
The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome.
JACC. Advances, 5(1), 102465
Citation
Kumar, Sonal; Anderson, John E; Coviello, Andrea; Lopez-Jimenez, Francisco; Bakris, George L. (2026). The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome.. JACC. Advances, 5(1), 102465. https://doi.org/10.1016/j.jacadv.2025.102465